The Effect of Efudex Treatment on Photoaged Skin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00121511
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : May 27, 2015
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Dana L. Sachs, MD, University of Michigan

Brief Summary:

The researchers propose that skin improvements may be seen following a course of Efudex, (5-fluorouracil), a FDA-approved topical therapy (applied directly to the skin). These improvements could be the result of both a reduction of actinic keratoses (small red horny growths or flesh-colored wartlike growths caused by overexposure to ultraviolet radiation or the sun) and improvement of sun-damaged skin.

In addition, this research study is being done to determine if the expression of p53, a tumor suppressor gene (its activity stops the formation of tumors), is decreased following Efudex treatment. Mutations (abnormal changes) in the gene, called p53, are associated with a certain type of skin cancer. In addition, p53-mutated genes are known to exist in non-cancerous sun-damaged skin. Thus, the presence of p53 mutations may serve as a marker for both sun damage and an elevated risk of developing skin cancer.

Condition or disease Intervention/treatment Phase
Photo-aging Keratosis Drug: Efudex (5-fluorouracil) Not Applicable

Detailed Description:

Efudex (5-fluorouracil) has been used as topical chemotherapy for the treatment of actinic keratoses (AKs) since the 1950's. Through many years of use, Efudex has been deemed to be a safe and effective therapy. It requires, however, a high level of patient compliance and is known to cause a vigorous inflammatory reaction when actinic keratoses are treated. It has the distinct advantage of identifying precancerous skin lesions not apparent on clinical inspection or palpation. Following a course of Efudex to the face, patients have been noted to have fewer signs of dermatoheliosis.

The investigators propose to determine if Efudex is associated with improvement of aging skin in the setting of treating actinic keratoses. The researchers hope to demonstrate less p53 staining following Efudex treatment. It is proposed that the skin improvements seen following a course of Efudex are due to both reduction of actinic keratoses and impact on photoaging. The researchers propose to quantify the effects of Efudex therapy on the immunohistochemical staining properties of facial skin with respect to p53 and procollagen. The hypothesis is that Efudex therapy will decrease p53 immunostaining thus providing biochemical evidence to support this treatment in the reduction of actinic keratoses with concomitant improvement of aging skin.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Efudex (5-fluorouracil) Treatment on Photoaged Skin
Study Start Date : July 2005
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Actinic Keratoses resolution and improvement in photoaging

Secondary Outcome Measures :
  1. Changes in p53 immunostaining intensity will be used to assess response
  2. Collagen production will be evaluated by Western blotting, immunohistology, and RT-PCR

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 50 or older of either gender.
  • Patients must have actinic keratoses
  • Patients must have clinical photoaging judged by rhytides, dyspigmentation, poikiloderma, lentigines, skin thinning, and/or telangiectases.
  • Subjects must be in generally good health and willing to undergo skin biopsies from the face.
  • Subjects must be willing and able to comply with the requirements of the protocol.
  • You must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.

Exclusion Criteria:

  • Oral retinoid therapy (such as Accutane) within two months of study entry.
  • Topical retinoid, imiquimod, or diclofenac therapy within 2 months of study entry.
  • Prior laser re-surfacing, chemical peels for actinic keratoses or aging skin.
  • Pregnant or nursing subjects.
  • Non-compliant subjects.
  • Subjects with a significant medical history or concurrent illness that the investigator feels is not safe for study participation.
  • Prior systemic treatment with 5-fluorouracil.
  • Known history of allergy to lidocaine (numbing medication), 5-fluoruracil, or any other known components of Efudex.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00121511

United States, Michigan
University of Michigan Department of Dermatology
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
Valeant Pharmaceuticals International, Inc.
Study Chair: John J Voorhees, MD University of Michigan

Responsible Party: Dana L. Sachs, MD, Professor of Dermatology, Medical School, University of Michigan Identifier: NCT00121511     History of Changes
Other Study ID Numbers: Derm 549
First Posted: July 21, 2005    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015

Keywords provided by Dana L. Sachs, MD, University of Michigan:
Actinic Keratoses
5 fluorouracil

Additional relevant MeSH terms:
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs